Skip to main content
Erschienen in: Osteoporosis International 3/2012

01.03.2012 | Original Article

Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial

verfasst von: S. L. Silverman, K. Nasser, S. Nattrass, B. Drinkwater

Erschienen in: Osteoporosis International | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Summary

We examined how the use of bone turnover markers and educational information affects persistence of bisphosphonate use in osteoporotic patients. We found that reporting bone turnover results and/or educational information did not affect persistence.

Introduction

Long-term adherence and persistence to osteoporosis medication are poor. We examined whether reporting of bone turnover marker results, education about osteoporosis, or a combination of both would increase persistence to oral bisphosphonates.

Methods

Two hundred and forty women who were 5 years postmenopausal with BMD at least 2.0 standard deviations below normal were recruited for the study. All women were given a new prescription for alendronate and randomly assigned to one of four groups: (1) bone marker results at baseline, 3 and 12 months; (2) educational materials every month and a membership in the National Osteoporosis Foundation; (3) bone marker and educational information; and (4) control, no information other than usual care. Persistence among randomization groups was tested using survival analysis adjusting for the delay between intervention methods.

Results

Of those filling their initial prescription, 95.5% refilled their prescription at the end of the first month, 87% at 3 months, 82% at 6 months, and 78% at 10 months. Overall persistence through 12 months was 54%. There was no difference found among the four groups for persistence time using (p > 0.58).

Conclusion

Providing bone turnover marker results is not an effective way to enhance early compliance and persistence with drug therapy. While the women in our study felt that bone marker results and educational information were helpful to them, there was no difference in persistence between those who received either bone marker information and/or educational information and those who did not. Because of the unexpected rate of primary nonadherence, this study may be underpowered.
Literatur
1.
Zurück zum Zitat Silverman S, Schein JR (2001) Physician-patient decision making in osteoporosis management. J Musculoskel Med 18:124–130 Silverman S, Schein JR (2001) Physician-patient decision making in osteoporosis management. J Musculoskel Med 18:124–130
2.
Zurück zum Zitat Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82(12):1493–1501PubMedCrossRef Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82(12):1493–1501PubMedCrossRef
3.
Zurück zum Zitat Rubin SM, Cummings SR (1992) Results of bone density information affect women’s decisions about taking measures to prevent fractures. Ann Intern Med 116:990–995PubMed Rubin SM, Cummings SR (1992) Results of bone density information affect women’s decisions about taking measures to prevent fractures. Ann Intern Med 116:990–995PubMed
4.
Zurück zum Zitat Silverman S, Drinkwater B (1997) Effect of bone density information on decision making about estrogen. Obstet Gynecol 89:321–325PubMedCrossRef Silverman S, Drinkwater B (1997) Effect of bone density information on decision making about estrogen. Obstet Gynecol 89:321–325PubMedCrossRef
5.
Zurück zum Zitat Cummings SR, Palermo L, Browner W et al (2000) Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to mean. JAMA 283:1318PubMedCrossRef Cummings SR, Palermo L, Browner W et al (2000) Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to mean. JAMA 283:1318PubMedCrossRef
6.
Zurück zum Zitat Papanioannou A, Parkinson W, Adachi J et al (1998) Women’s decisions about taking measures to prevent fractures. Can Med Assoc J 15(10):1253–1257 Papanioannou A, Parkinson W, Adachi J et al (1998) Women’s decisions about taking measures to prevent fractures. Can Med Assoc J 15(10):1253–1257
7.
Zurück zum Zitat Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, May F, Patrick AR, Shrank WH, Solomon DH (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20:2127–2134. doi:10.1007/s00198-009-0976-0 PubMedCrossRef Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, May F, Patrick AR, Shrank WH, Solomon DH (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20:2127–2134. doi:10.​1007/​s00198-009-0976-0 PubMedCrossRef
8.
Zurück zum Zitat Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123PubMedCrossRef Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123PubMedCrossRef
9.
Zurück zum Zitat Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB, Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296–1304PubMedCrossRef Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB, Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296–1304PubMedCrossRef
10.
Zurück zum Zitat Physician’s guide to prevention and treatment of osteoporosis (2003) National Osteoporosis Foundation; Washington D.C. Physician’s guide to prevention and treatment of osteoporosis (2003) National Osteoporosis Foundation; Washington D.C.
11.
Zurück zum Zitat Fraenkel L, Gulanski B, Wittink D (2007) Patient willingness to take teriparatide. Patient Educ Couns 65(2):237–244PubMedCrossRef Fraenkel L, Gulanski B, Wittink D (2007) Patient willingness to take teriparatide. Patient Educ Couns 65(2):237–244PubMedCrossRef
12.
Zurück zum Zitat Ratcliffe J, Buxton M, McGarry T, Sheldon R, Chancellor J (2004) Patients’ preferences for characteristics associated with treatments for osteoarthritis. Rheumatology 43:337–345PubMedCrossRef Ratcliffe J, Buxton M, McGarry T, Sheldon R, Chancellor J (2004) Patients’ preferences for characteristics associated with treatments for osteoarthritis. Rheumatology 43:337–345PubMedCrossRef
13.
Zurück zum Zitat Potts M, Weinberger M, Brandy KD (1984) Views of patients and providers regarding the importance of various aspects of an arthritis treatment program. J Rheumatol 11:71–75PubMed Potts M, Weinberger M, Brandy KD (1984) Views of patients and providers regarding the importance of various aspects of an arthritis treatment program. J Rheumatol 11:71–75PubMed
14.
Zurück zum Zitat Fraenkel L, Gulanski B, Wittink D (2006) Patient treatment preferences for osteoporosis. Arthritis Rheum 55(5):729–735PubMedCrossRef Fraenkel L, Gulanski B, Wittink D (2006) Patient treatment preferences for osteoporosis. Arthritis Rheum 55(5):729–735PubMedCrossRef
Metadaten
Titel
Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial
verfasst von
S. L. Silverman
K. Nasser
S. Nattrass
B. Drinkwater
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 3/2012
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-011-1721-z

Weitere Artikel der Ausgabe 3/2012

Osteoporosis International 3/2012 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.